Protalix BioTherapeutics Q2 2025 Earnings Call Transcript: A Detailed Review of Financial Results and Business Update

Protalix BioTherapeutics reported Q2 2025 earnings, with CEO Dror Bashan highlighting accomplishments and Eyal Rubin reviewing financial results. Bashan mentioned recent business updates and growth, while Rubin discussed the company's financial performance. The call was hosted by Mike Moyer of LifeSci Advisors.

Protalix BioTherapeutics, Inc. (PLX) reported its financial results for the second quarter and six months ended June 30, 2025, with the company showcasing significant growth in revenues and an improvement in net income. The company's CEO, Dror Bashan, and CFO Eyal Rubin provided updates during a conference call hosted by Mike Moyer of LifeSci Advisors.

Second Quarter 2025 Highlights

For the second quarter, Protalix reported revenue of USD 15.66 million, a 16% increase compared to USD 13.47 million in the same period last year. This growth was primarily driven by a USD 8.0 million increase in sales to Chiesi, partially offset by decreases in sales to Fiocruz (Brazil) and Pfizer. Net income for the quarter was USD 0.164 million, compared to a net loss of USD 2.2 million in the same period last year. Basic and diluted loss per share from continuing operations was USD 0.04, down from USD 0.09 a year ago.

Six-Months Ended June 30, 2025 Highlights

For the six months, Protalix reported revenue of USD 25.77 million, a 50% increase compared to USD 17.22 million in the same period last year. Net loss for the six months was USD 3.46 million, compared to a net loss of USD 6.8 million in the same period last year. Basic and diluted loss per share from continuing operations was USD 0.04, down from USD 0.09 a year ago.

Business and Clinical Updates

CEO Bashan highlighted the company's growth in revenues, driven primarily by sales of Elfabrio® to Chiesi, which represents a global market of approximately USD 2.3 billion currently and is forecasted to grow to USD 3.2 billion by 2030. Bashan also mentioned that the company anticipates initiating a randomized Phase 2 trial for PRX-115 in the second half of 2025 and enrolling the first patient in the fourth quarter of 2025.

Financial Performance and Management Changes

CFO Rubin discussed the company's financial performance, noting that the increase in research and development expenses was primarily due to preparations for the planned phase II clinical trial of PRX-115. He also mentioned that the company expects to continue to incur significant, increasing research and development expenses as it enters more advanced stages of preclinical and clinical trials for certain product candidates.

Rubin announced that Eyal Rubin is stepping down as the company's Chief Financial Officer after six years of dedicated service. He will be succeeded by Gilad Mamlok, a seasoned financial executive with deep experience in healthcare and technology companies. The appointment of Gilad Mamlok was effective August 24, 2025, and he will work alongside Rubin until October 2025 to ensure a seamless transition.

Conference Call Details

The conference call to review the financial results and provide a business update was hosted on August 14, 2025, at 8:30 am EDT. Participants could dial the following numbers to join:

- Toll Free: 1-877-423-9813
- International: 1-201-689-8573
- Israeli Toll Free: 1-809-406-247
- Conference ID: 13755073

The webcast was available via the Protalix website and the following links:

- Company Link: [https://ir.protalix.com/news-events/events](https://ir.protalix.com/news-events/events)
- Webcast Link: [https://tinyurl.com/yc272tbr](https://tinyurl.com/yc272tbr)

References

[1] [Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025](https://www.marketscreener.com/news/protalix-biotherapeutics-inc-reports-earnings-results-for-the-second-quarter-and-six-months-ended-ce7c51d9dd80f627)
[2] [Protalix BioTherapeutics Reports Second Quarter 2025 Earnings](https://finance.yahoo.com/news/protalix-biotherapeutics-reports-second-quarter-105000636.html)